Psychotherapy | Medication | Diagnosis | Mean age of sample | % female in sample | N se | Treatment duration (weeks) | N rand | Country | |
---|---|---|---|---|---|---|---|---|---|
Browne 2002[26] | IPT | Sertraline (SSRI) | Dys, DD | 42.2 | 68 | 12 | 24 | 476 | Canada |
deMello 2001[27] | IPT | Moclobemide | Dys, DD | 38.8 | 80 | 16 | 32 | 35 | Brazil |
Keller 2000[28] | CBASP | Nefazodone | cMD, rec, DD | 43.0 | 65 | 16 | 12 | 453 | USA |
Kocsis 2009[13] | CBASP/BSP | SSRIs | cMD, rec, DD | 45.4 | 55 | 16/18 | 12 | 491 | USA |
Markowitz 2005[29] | IPT | Sertraline (SSRI) | Dys | 42.3 | 63 | 16 | 16 | 45 | USA |
Miller 1999[30] | CBT | Amitriptyline/Desipramine | Dys | 37.4 | 81 | 40 | 20 | 26 | USA |
Ravindran 1999[31] | CBT | Sertraline (SSRI) | Dys | 38.0 | 58 | 12 | 12 | 47 | Canada |
Schramm 2008[32] | IPT | Sertraline (SSRI)/Amitriptyline | cMD, DD | 42.8 | 67 | 15 | 5 | 45 | Germany |